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Available online 11 April 2016Traumatic brain injury (TBI) in humans can result in permanent tissue damage and has been linked to cognitive
impairment that lasts years beyond the initial insult. Clinically effective treatment strategies have yet to be devel-
oped. Transplantation of human neural stem cells (hNSCs) has the potential to restore cognition lost due to
injury, however, the vast majority of rodent TBI/hNSC studies to date have evaluated cognition only at early
time points, typically b1 month post-injury and cell transplantation. Additionally, human cell engraftment and
long-term survival in rodent models of TBI has been difﬁcult to achieve due to host immunorejection of the
transplanted human cells, which confounds conclusions pertaining to transplant-mediated behavioral improve-
ment. To overcome these shortfalls, we have developed a novel TBI xenotransplantation model that utilizes
immunodeﬁcient athymic nude (ATN) rats as the host recipient for the post-TBI transplantation of human em-
bryonic stem cell (hESC) derived NSCs and have evaluated cognition in these animals at long-term (≥2 months)
time points post-injury. We report that immunodeﬁcient ATN rats demonstrate hippocampal-dependent spatial
memory deﬁcits (Novel Place, Morris Water Maze), but not non-spatial (Novel Object) or emotional/anxiety-
related (Elevated Plus Maze, Conditioned Taste Aversion) deﬁcits, at 2–3 months post-TBI, conﬁrming that
ATN rats recapitulate some of the cognitive deﬁcits found in immunosufﬁcient animal strains. Approximately
9–25% of transplanted hNSCs survived for at least 5 months post-transplantation and differentiated into mature
neurons (NeuN, 18–38%), astrocytes (GFAP, 13–16%), and oligodendrocytes (Olig2, 11–13%). Furthermore, while
this model of TBI (cortical impact) targets primarily cortex and the underlying hippocampus and generates a
large lesion cavity, hNSC transplantation facilitated cognitive recovery without affecting either lesion volume
or total spared cortical or hippocampal tissue volume. Instead, we have found an overall increase in host hippo-
campal neuron survival in hNSC transplanted animals and demonstrate that a correlation exists between
hippocampal neuron survival and cognitive performance. Together, these ﬁndings support the use of immunode-
ﬁcient rodents inmodels of TBI that involve the transplantation of human cells, and suggest that hNSC transplan-
tation may be a viable, long-term therapy to restore cognition after brain injury.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Traumatic brain injury








Traumatic brain injury is a serious, debilitating condition that arises
from an injury to the head due to blunt or penetrating trauma or from
acceleration/deceleration forces. TBI affects upwards of 3.5 million
people per year (Coronado et al., 2012), and there is an estimated 5.3
million people in the United States alone living with permanent, long-
term TBI-related disabilities (Griesbach et al., 2015). However,Health ScienceRoad, University
. This is an open access article underthese numbers likely underestimate the true incidence of TBI due to
underreporting of sports- and military-related injuries, and persons
whonever seek healthcare (Roozenbeek et al., 2013). To date, treatment
options for TBI focus on patient stabilization immediately after
injury and subsequent long-term rehabilitative care. Considering that
many pharmacologic interventions for TBI have been shown to be inef-
fective in clinical trials (Xiong et al., 2009; Maas et al., 2010; Lu et al.,
2012), new treatment options must be explored. Stem cell transplanta-
tion has the potential to improve functional outcome after central
nervous system (CNS) trauma and disease (Cummings et al., 2005; Xu
et al., 2006; Ebert et al., 2008; Walker et al., 2009; Zhang and Chopp,
2009; Tetzlaff et al., 2011; Lindvall et al., 2012; Chen et al., 2014a;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 D.L. Haus et al. / Experimental Neurology 281 (2016) 1–16Rosser and Svendsen, 2014; Thomsen et al., 2014; Levy et al., 2015; Tsai
et al., 2015;Wang et al., 2016). In the context of TBI, the transplantation
of bone-marrow derived mesenchymal/stromal cells has been exten-
sively studied (Li and Chopp, 2009; Aertker et al., 2015) and several
clinical trials utilizing human mesenchymal stem cells have been
approved and are upcoming (NCT02525432, NCT02416492),
ongoing (NCT02028104, NCT01851083) or have been completed
(NCT00254722, NCT01575470). However, transplanted humanmesen-
chymal/stromal cells typically do not survive long-term in TBI rodent
models (Gold et al., 2013). Poor cell survival, a rejection response,
and/or failure to quantify cell survival can hinder the ability to accurate-
ly assess long-term cellular contribution to repair and recoverywhen ei-
ther cell replacement and/or long-term transplant-mediated trophic
support or immunemodulation are putativemechanism(s) of action.
Additionally, while there is evidence that suggests that short-term
human cell transplant survival is sufﬁcient to promote behavioral re-
covery after CNS injury and disease (Redmond et al., 2007; Teng
et al., 2011; Huang et al., 2014), a treatment option with the poten-
tial for sustained beneﬁts provided by a cell population that survives
long-term will be of great use for treating prolonged impairments or
impairments that may not manifest for months post-injury.
To enable the evaluation of continuous, long-term repair in animal
models, the survival of transplanted cells must be improved. To achieve
both increased and prolonged transplanted human cell survival in
animal models of CNS injury and disease, the use of immunodeﬁcient
rodents (such as the NOD-scid mouse and athymic nude or ATN rat)
has been shown to support enhanced transplanted human cell survival
(Nasonkin et al., 2009; Anderson et al., 2011; Gowing et al., 2014;Mattis
et al., 2014; Xu et al., 2015). Additionally, transplantation of phenotyp-
ically similar CNS-derived neural stem cells into the brain or spinal
cord, as opposed to transplantation of foreign blood- or bone marrow-
derived stem cells, may also improve transplanted cell survival.
Therefore, in this study we have utilized immunodeﬁcient ATN rats
as our TBI model and transplanted previously characterized hESC-
derived NSCs that have undergone selective cell sorting to enrich for
the stemness marker CD133, a process that was shown to increase
both in vitro expansion potential and neuronal differentiation without
increasing the risk of teratoma formation in vivo (Haus et al., 2014).
In addition to achieving improvements in transplanted human cell
survival, there is also a need for future TBI and cell transplantation
studies to be evaluated at long-term timepoints (≥2months). Assessing
only early cell survival and behavioral recovery poses two problems:
1) If hNSC engraftment and subsequent integration is integral to
behavioral recovery, evaluation at later time points becomes critical as
transplanted human cells will likely require at a minimum several
months to fully integrate and differentiate into mature neural cell
types, and 2) If long-term behavioral improvement is the desired
clinical outcome, evaluation of recovery within days to weeks of injury
or treatment is not informative for long-term behavioral gains. Howev-
er, themajority of studies conducted to date assessing the effect of hNSC
transplantation into rodent models of TBI have evaluated transplanted
cell survival and behavioral recovery only at very early (typically 1–
2 weeks) time points post-injury or cell transplantation (Gold et al.,
2013).
To our knowledge, no studies to date have assessed behavioral
impairment after cortical impact TBI in ATN rats. Therefore, the ﬁrst
objective of this study was to assess whether and what type of long-
term (≥2 months) behavioral impairments exist post-TBI in an
immunodeﬁcient, ATN model of TBI. In the studies described herein,
we have evaluated a broad spectrum of behavioral tasks that could be
affected by TBI, including the Morris Water Maze (spatial memory,
motor element), Novel Place Recognition (spatial memory), Novel
Object Recognition (object memory), Elevated Plus Maze (anxiety),
and Conditioned Taste Aversion (classical conditioning). Following
this ﬁrst set of studies that evaluated long-termbehavioral performance
in ATN rats after TBI, we then tested the hypothesis that intracranialtransplantation of human embryonic stem cell-derived neural stem
cells can promote long-term histopathological improvement (i.e.
reduced lesion volume and/or increased neuronal sparing) and
cognitive behavioral recovery after TBI.
2. Materials and methods
2.1. Animal use and controlled cortical impact (CCI) TBI
All animal housing conditions, surgical procedures, and postopera-
tive care was approved by and conducted according to the Institutional
Animal Care and Use Committee (IACUC) guidelines at the University of
California, Irvine. Adult male athymic nude (ATN) rats (NCI RNU−/−
homozygous, 10–11 weeks old; Charles River Laboratories, San Diego,
CA) were housed 2 per cage on a 12 hour light/dark cycle with free
access to food and water. Unilateral cortical contusions were carried
out under isoﬂurane anesthesia (3%)with rats positioned in a stereotax-
ic holder (Leica Microsystems Inc.). Injuries were produced using a
pneumatic controlled cortical impact device (TBI 0310; Precision
Systems and Instrumentation, Fairfax Station, VA) with a 5 mm ﬂat
metal impactor tip. The depth of the impact was set at 2.5 mm with a
velocity of 4.5 m/s and a dwell time of 500 ms. TBI coordinates were:
A/P− 4.5mm,M/L− 3.6mm(left cortex, centered over hippocampus);
prior to impact, a 6 mm bone ﬂap was removed using a manual
trephine.
All animals received lactated ringers (50 ml/kg) subcutaneously
immediately after surgery as well as Buprenorphine (0.5mg/kg) immedi-
ately after surgery and for 2 days thereafter. Additionally, due to the im-
munodeﬁcient nature of ATN rats, an antibiotic (Baytril, 2.5 mg/kg) was
administered immediately after surgery and daily for 5 days thereafter.
2.2. Human neural stem cell preparation and transplantation
Culture of Xeno-Free CD133+/CD34− Shef6 hNSCswas established
at UC Irvine as previously described (Haus et al., 2014) and in
accordancewith all appropriate hSCRO and IBC protocols. hNSC passage
number at the time of transplantation was either passage 7 (P7, “low
passage”) or passage 27 (P27, “high passage”). At the passages utilized,
both Shef6 hNSC lines were N70% CD133+, contained b5% CD34+
expressing cells, exhibited predominantly neuronal differentiation
in vitro, and were karyotypically normal. All hNSC and vehicle prepara-
tions took place during the day of transplantation/injection. All cells
were maintained under normal culture conditions prior to harvesting
and collection for transplantation. For hNSC injections, cells were
dissociated to single cells using TrypLE and resuspended in X-Vivo 15
to yield 7.5 × 104 cells/μl. Vehicle solution consisted of X-Vivo 15 cell
culture media. During surgical procedures, all hNSC and vehicle
preparations were kept at room temperature.
Animals were randomly allocated to different groups: sham (n =
10), vehicle injection (n = 12), and hNSC transplantation (n = 13
Shef6 P27, n = 11 Shef6 P7) and were processed blind to injection
cohort. All hNSC and vehicle injections occurred 9 days post-TBI.
Previously injured ATN rats were anesthetized with 3% isoﬂurane and
positioned in a stereotaxic holder (Leica Microsystems Inc.). A Dremel
rotary tool set at ~5000 rpm was used to create injection burr holes. A
5 μl Hamilton syringe (Cat #87930) with a 1″ 30G blunt needle was
mounted into an UMP-3 (World Precision Instruments) injector
connected to a SYS-Micro4 Controller. A total of four injections of either
hNSCs or vehicle were made at the following coordinates: 1) Anterior
Hippocampus (A/P−2.50, M/L +1.20, D/V−3.70), 2) Anterior Corpus
Callosum (A/P −2.50, M/L +1.20, D/V −2.45), 3) Posterior Corpus
Callosum (A/P−5.05, M/L +1.00, D/V−2.90), and 4) Posterior Hippo-
campus (A/P−5.05, M/L +4.00, D/V−3.90). Cells were ﬁrst triturated
5 timeswith a 10 μl pipette then pulled up into the syringe over approx-
imately 10 s. For each injection, the needle was initially lowered an
additional 0.15 mm to create a pocket in the brain. For each of the
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7.5 × 104 cells/μl) over 2 min (for a total dose of 2.5 × 105 cells). Speeds
varied relative to total volume, but time of injection remained constant.
The needle was raised out of the brain 4 min after injection. The syringe
was tested to make sure it was not clogged by ejecting some of the
solution into the air manually through the Micro4 controller. Bone
wax was applied to seal the burr hole.
Animals received lactated ringers (50ml/kg) subcutaneously imme-
diately after surgery, Buprenorphine (0.5 mg/kg) immediately after
surgery and for 2 days thereafter, and Baytril (2.5 mg/kg) immediately
after surgery and daily for 5 days thereafter. No immunosuppressant
drugs were administered.
2.3. Cognitive behavioral analysis
2.3.1. Novel place and object recognition
Behavioral setup and analysis was based on previously published
protocols (Acharya et al., 2009). All testing was done by experimenters
blind to treatment group. Two open ﬁeld plastic arenas, eachmeasuring
45 × 70 × 70 cmwere used for novel place recognition (NPR) and novel
object recognition (NOR) testing. The arenas were placed next to each
other on the ﬂoor of a brightly lit, dedicated behavioral testing room.
A video camera was centered on the ceiling above the arenas, and live
tracking of the animals was achieved using Noldus Ethovision XT
(Noldus Information Technology). For familiarization testing, two iden-
tical objects were placed in opposing corners of the open ﬁeld. For NPR
testing, 24 h later one of these objects was moved to an open corner
(‘novel place’), while the other block remained at its former spatial
location (‘familiar place’). For NOR testing, 24 h later the object placed
in the open corner (‘novel place’) was removed and replaced with a
new, unfamiliar object (‘novel object’). Small pieces of white Velcro
placed on the undersides of the objects and on the arena ﬂoor were
used to secure the objects in place during testing. Arenas and objects
were cleanedwith a 0.1% acetic acid solution between trials tominimize
odor cues.
To minimize animal stress, the experimenter handled all animals
daily for 1 week before starting NPR testing. For the familiarization
phase, rats were placed in the arenas and allowed to explore freely for
5 min. For the retention phases, rats were then returned to their home
cages for 24 h before being placed in the test arena again for the test
phase, during which they were allowed to explore freely for 3 min.
For all phases, the “head direction to zone” function in Ethovision XT
was used to track exploration of the objects. A rat was considered to
be exploring a block when its head was oriented towards it and its
nose was within a 4-cm radius.
Discrimination index, calculated as the ratio of total time spent
exploring the novel spatial location or novel object in relation to the fa-
miliar spatial location or object (tnovel− tfamiliar / tnovel + tfamiliar)
was used as themain dependentmeasure. Previous research has shown
that preference for the novel place can diminish after the ﬁrst 1–2 min
of testing, as the spatial locations becomeequally familiar to the animals
(Mumby et al., 2002). During our NPR analysis we observed similar
results; therefore, data from only the ﬁrst 2 min of the 3 min test
phase was included due to the diminished preference for the novel
place during the thirdminute of testing. Animals that did not explore ei-
ther object during testing were excluded from analysis.
2.3.2. Morris Water Maze acquisition and reversal
The Morris Water Maze (MWM) consisted of a circular ﬁberglass
pool ﬁlled with heated water made opaque by adding non-toxic white
paint. A video camera suspended above the pool recorded the animals
and video output was recorded by an EthoVision tracking system
(Noldus, Leesburg, VA). Visual cues were placed on the four walls sur-
rounding the pool. The water maze protocol included 5 phases: cued
learning, spatial acquisition training, probe test, spatial reversal training,
and a second probe test. Twenty-four hours prior to spatial acquisitiontraining, the animals were allowed to adapt to the maze for 60 s in a
cued learning phase inwhich the hidden platformwasﬂagged to enable
easy location and visual cueswere removed from the surroundingwalls.
Spatial acquisition training: Twenty-four hours following cued
learning, the animals were placed back into the same pool with the
ﬂag removed from the hidden platform and visual cues placed back
onto the surrounding walls. The animals were then required to swim
to ﬁnd a hidden platform submerged just below the water surface.
Training consisted of 4 trials per day for 5 consecutive days. For each
trial, the animals were placed into the water facing the pool wall at
one of four different starting positions (N, S, E, and W) chosen in
semi-random order. During each trial, the rats were allowed to swim
freely until they reached the hidden platform and remained for 10 s.
Rats that failed to ﬁnd the hidden platform in 60 s were guided to the
platform location. Probe test: Twenty four hours after the ﬁnal spatial
acquisition training trial, the rats were returned to the pool and placed
in a new location with the hidden platform absent for 60 s. The rats
swim path and number of times crossing the former platform location
was recorded.
Spatial reversal training: After the spatial acquisition learning task
and initial probe test was completed, a reversal learning protocol was
conducted. During reversal learning, the hidden platform was moved
to the opposite quadrant. Reversal learning consisted of 5 additional
days of training with 4 trials per day, similar to spatial acquisition
training. Probe test: Twenty-four hours after the ﬁnal reversal training
trial, the rats were returned to the pool and placed in a new location
with the hidden platform absent for 60 s. The rats' swim path and num-
ber of times crossing the former platform location was recorded.
2.3.3. Elevated Plus Maze
The Elevated PlusMaze (EPM) consisted of two open and two closed
arms fabricated from black plastic (Med Associates Inc.). The apparatus
was situated in a dark room, and experiments were recorded using
infrared beam detection and an infrared video camera suspended
above the plus maze. Live tracking of the animals was achieved using
Noldus Ethovision XT (Noldus Information Technology). Each rat was
placed in the center of the plus maze facing one of the open arms and
allowed to explore for a total of 5 min. Total time spent in the open
and closed arms was recorded as well as open and closed arm entries
(counted when the center point of the rat crossed into either the open
or closed arms). The apparatus was cleaned prior to the introduction
of each animal. Rats were tested on the maze in randomized order.
2.3.4. Conditioned Taste Aversion
Behavioral setup and analysis was based on a previously published
protocol (Lopez-Velazquez et al., 2007). Prior to Conditioned Taste
Aversion (CTA) testing, the rats were deprived of water for 24 h and
given drinking access for 10 min twice a day for 6 days. On Day 7
(acquisition) the water was replaced with saccharin solution (0.1%).
20 min later the rats were injected with LiCl (7.5 ml/kg i.p., 0.2 M) to
induce gastric malaise or taste aversion. On Days 8–10 water was
given in the morning and afternoon sessions to obtain baseline
consumption. Beginning on the morning of Day 11, the water given
was substitutedwith a freshlymade 0.1% saccharin solution to test aver-
sion (Day 11) and then extinction (Days 12–22).
2.4. Immunohistochemistry
At 20 week post-transplantation, tissue collection and immunohis-
tochemistry was performed as previously described (Hooshmand
et al., 2009)withminormodiﬁcations. Brieﬂy, all animalswere anesthe-
tized with a lethal dose of Euthasol (100 mg/kg, i.p.) and transcardially
perfused with 50 ml of PBS, followed by 300–400 ml of 4% paraformal-
dehyde. Brains were carefully dissected and post-ﬁxed overnight in a
solution of 4% paraformaldehyde and 20% sucrose in PBS at 4 °C, ﬂash
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−80 °C.
For cryosectioning and immunohistochemistry, frozen brains were
embedded in Optimal Cutting temperature (O.C.T.) compound (Sakura
FinetekUSA, Inc.). 30 μmthick coronal sectionswere cut using a cryostat
and sections mounted using a CryoJane tape transfer system (Leica
Biosystems, Inc., Buffalo Grove, IL). All tissue sections were antigen-retrieved and immunostaining procedures were conducted at room
temperature. For 3,3′-diaminobenzidine (DAB) immunohistochemistry,
sectionswereﬁrst washed in 0.1M Tris followed by a 15min incubation
in 0.3% hydrogen peroxide/methanol. For ﬂuorescent immunohisto-
chemistry, wash and blocking steps were performed using PBS rather
than Tris. After a brief 0.1% Triton X-100 wash, sections were blocked
for 1 h with bovine serum albumin (BSA) and normal serum from the
5D.L. Haus et al. / Experimental Neurology 281 (2016) 1–16species in which the secondary antibodywas raised. Sectionswere then
exposed overnight to the appropriate primary antibody. The primary
antibodies used were: monoclonal mouse anti-SC121 (DAB-1:8000,
Fluorescent-1:500) (AB-121-U-050, Clontech/Takara), polyclonal rabbit
anti-hNestin (1:1000) (ABD69, Millipore), polyclonal rabbit anti-Olig2
(1:500) (AB9610, Millipore), polyclonal rabbit anti-NeuN (1:1000)
(ABN78, Millipore), monoclonal mouse anti-APC (CC1) (1:200) (OP80,
Calbiochem), polyclonal goat anti-Doublecortin (1:200) (SC-8066,
Santa Cruz Biotechnology), and polyclonal rabbit anti-Glial Fibrillary
Acidic Protein, GFAP (1:1000) (Z0334, DAKO). The next day, sections
were incubated with either ﬂuorescent or biotin-conjugated, puriﬁed
IgG secondary antibody (1:500, Jackson Immunoresearch) pre-
adsorbed against the species in which the primary was raised,
followed by avidin-biotinylated peroxidase complex (ABC) using a
Vectastain Elite ABC kit (Vector Laboratories, USA) prepared according
to the manufacturer's recommendations (for DAB staining). After
several washes, the signal was visualized with diaminobenzidine
(DAB) (Vector Laboratories, USA). Sections were mounted onto slides
and allowed to dry overnight at 37 °C. DAB stained sectionswere lightly
counterstained with Cresyl Violet. Fluorescent stained sections
were counterstained with Hoechst 33342 (1:500, Life Technologies).
All slides were coverslipped using Depex or Fluoromount-G
(SouthernBiotech) mounting medium. Imaging was performed using
a Zeiss Imager.M2 Apotome System (Carl Zeiss) and a Zeiss Observer.Z1
Spinning Disk System (Carl Zeiss).
2.5. Quantiﬁcation of histology
2.5.1. Lesion, spared tissue, and ventricle volume analysis
Histological sections comprised of the entire rostral to caudal extent
containing cortex (approx. A/P +5.16 to A/P −9.36) were used to
estimate total brain volume, lesion volume, spared tissue (hippocam-
pus, neocortex) volume, and lateral ventricle volume. Unbiased
stereological analysis was performed using a Zeiss Imager.M2 Apotome
System (Carl Zeiss) and Microbrightﬁeld Stereoinvestigator version
11.01.1 (MBF Bioscience) Cavalieri probe. A section interval of 1/12
was utilized, placing adjacent sections analyzed at 360 μm apart from
each other. Cresyl violet was used to counterstain tissue sections for
histological structure identiﬁcation. Contours were drawn at 2.5×
objective outlining the brain regions of interest and within them
counting grids placed, including left/right hemisphere (grid size:
2000 μm), left/right hippocampus (500 μm), left/right neocortex
(500 μm), left/right lateral ventricle (350 μm), lesion (1000 μm), and
other non-tissue space (350 μm). The described analysis provided an
average coefﬁcient of error (CE, m = 1) ratio of b0.05 for all regions
quantiﬁed.
2.5.2. Hippocampal neuron survival analysis
Histological sections comprised of the anterior dorsal hippocampus
(approx. A/P−1.72 to A/P−4.56)were used to estimate total neuronal
survival in both the injured hemisphere dentate gyrus and combined
Cornu Ammonis (CA) pyramidal cell layers (consisting of regions CA1,
CA2, and CA3) as well as the uninjured hemisphere dentate gyrus.
Unbiased stereological analysis was performed using a Zeiss Imager.M2Fig. 1. Controlled cortical impact TBI imparts long-term spatial memory impairments in immun
for cognition via the spatialmemory tasksNovel Place Recognition (NPR) and theMorrisWaterM
emotional/anxiety-related tasks such as the Elevated Plus Maze (EPM) and Conditioned Taste
dependent NPR deﬁcit during the ﬁrst 2 min of testing (one-tailed t-test t19 = 3.93, P b 0.00
zero (TBI, two-tailed t-test t10 = 1.25, P = 0.24). (C) There was no difference between
independent NOR task (one-tailed t-test t20 = 0.51, P = 0.31). (D) MWM acquisition analy
ﬁnding the hidden platform relative to sham animals. Two-way repeated measures ANOVA w
interaction (P = 0.06). (E) On Day 6, a Probe Trial revealed that TBI animals spent signiﬁcan
1.83, P b 0.05). (F) The platform location was then moved to a new location to test reversal le
increased escape latencies ﬁnding the hidden platform relative to sham animals. Two-way rep
trial × group interaction (P b 0.01). (G) On Day 12, a Probe Trial revealed that TBI animals s
tailed t-test t20 = 2.55, P b 0.01). *P b 0.05, **P b 0.01, ***P b 0.001. Data are presented asApotome System (Carl Zeiss) and Microbrightﬁeld Stereoinvestigator
(MBF Bioscience) Optical Fractionator probe. A section interval of 1/12
was utilized, placing adjacent sections analyzed at 360 μm apart from
each other. Cresyl violet was used to stain tissue sections for histological
structure identiﬁcation. Contours were drawn at 2.5× objective
outlining the brain regions of interest and neuronal identiﬁcation and
counting was performed at 100× magniﬁcation. Only large Nissl-
positive cells containing well deﬁned perikarya and dense ribosomes
were counted to limit quantiﬁcation to neurons. For all regions
analyzed, the counting frame utilized was 25 × 25 μmwith a grid size
of 150 × 150 μm. The dissector height was set at 13 μmwith an upper
and lower guard zone of 1 μm. The described analysis provided an
average coefﬁcient of error (CE, m = 1) ratio for all animals (n = 24–
30) of 0.074 (injured DG), 0.075 (injured CA), and 0.057 (uninjured
DG).
2.5.3. Transplanted human cell survival analysis
Histological sections comprised of the entire rostral to caudal extent
containing cortex (A/P +5.16 to A/P −9.36) were used to estimate
total human cell survival. Unbiased stereological analysis was per-
formed using a Zeiss Imager.M2 Apotome System (Carl Zeiss) and
Microbrightﬁeld Stereoinvestigator (MBF Bioscience) Optical Fraction-
ator probe by an observer blind to treatment group. A section interval
of 1/12 was utilized, placing adjacent sections analyzed at 360 μm
apart. An anti-SC121 (human cytoplasm) antibody was used to identify
human cells and Cresyl violet was used to counterstain tissue sections
for histological structure identiﬁcation. Contours were drawn at 2.5×
objective outlining areas of human cell engraftment, and human
cell identiﬁcation and counting was performed at 63× magniﬁcation.
The counting frame utilized was 50 × 50 μm with a grid size of
200 × 200 μm. The dissector height was set at 12 μm with an upper
and lower guard zone of 1 μm. The described analysis provided an aver-
age coefﬁcient of error (CE, m = 1) ratio for all hNSC transplanted
animals (n = 22) of 0.23.
2.5.4. Transplanted human cell fate analysis
Analysis was performed using a Zeiss Imager.M2 Apotome System
(Carl Zeiss) and Bitplane: Imaris Scientiﬁc 3D/4D Image Processing
and Analysis (Bitplane AG). A section interval of 1/24 was utilized,
placing adjacent sections analyzed at 720 μm apart from each other.
Co-localization was performed using either antibodies speciﬁc for neu-
rons (NeuN), astrocytes (GFAP), oligodendrocytes (Olig2), and undiffer-
entiated cells (Nestin) along with an anti-SC121 (human cytoplasm)
antibody. Hoechst 33342 was used as a nuclear counterstain. To esti-
mate the approximate number of cells of each fate for each animal, a
minimum of 3 semi-random images containing at least 10 human
cells were analyzed. Each fate group consisted of 4–6 animals.
2.6. Statistical analysis
All behavioral, histological, and stereological analyses were
performed by experimenters blinded to the experimental groups. Sta-
tistical analyses were performed using Prism (Version 6.0b Software).
Behavioral data for tasks comparing sham and TBI animals wereodeﬁcient ATN rats. Between 9 and 16weeks post-injury (WPI), (A) animals were assessed
aze (MWM), aswell as thenon-spatialmemory taskNovel Object Recognition (NOR) and
Aversion (CTA). (B) TBI animals (n = 11) exhibited a signiﬁcant 24-hour hippocampal-
1) when compared to sham animals (n = 10) that was not signiﬁcantly different from
TBI (n = 12) and sham (n = 10) groups as assessed via the 24-hour hippocampal-
sis revealed that on Days 2–5 TBI animals had signiﬁcantly increased escape latencies
as signiﬁcant for trial day (P b 0.0001) and group (P b 0.001), but not for trial × group
tly less time in the target quadrant compared to sham animals (one-tailed t-test t20 =
arning. MWM reversal analysis revealed that on Days 9–11, TBI animals had signiﬁcantly
eated measures ANOVA was signiﬁcant for trial day (P b 0.0001), group (P b 0.0001), and
pent signiﬁcantly less time in the target quadrant compared to sham animals (one-
mean ± s.e.m.
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or multiple (CTA) t-tests or via a repeated measures two-way ANOVA
(MWMAcquisition and Reversal), unless otherwise stated in the results
section. t-Test results reported as tdf = t-score, P value. For behavioral
tasks comparing sham, TBI + vehicle, and TBI + hNSCs, analysis was
performed using either unpaired two-tailed t-tests (NPR), repeated
measures two-way ANOVA (MWM Acquisition and Reversal), or
Pearson Correlation (MWMSlope) analysis. All stereological quantiﬁca-
tions were analyzed via unpaired two-tailed t-tests. Errors are the stan-
dard error (SEM) of averaged results. Signiﬁcance was deﬁned as at
least P b 0.05 for all statistical analyses.
3. Results
3.1. Immunodeﬁcient rats exhibit long-term cognitive impairment
following TBI
To improve the long-term survival of transplanted hNSCs, we
utilized immunodeﬁcient ATN rats as hNSC recipients. Because
zero studies to date have assessed the behavioral response of immuno-
deﬁcient ATN rats to TBI,multiple cognitivemeasureswere evaluated at
delayed (N2 months) time points post-injury (Fig. 1), including:
hippocampal-dependent spatial memory (Novel Place Recognition,
Morris Water Maze), non-spatial memory (Novel Object Recognition),
emotional/anxiety-related behavior (Elevated Plus Maze), and classical
conditioning (Conditioned Taste Aversion).
Spatialmemory deﬁcits are a hallmark of hippocampal injury, and in
our study, the injury location was centered on the cortex directly over-
lying the dorsal hippocampus. To verify the presence of hippocampal-
dependent spatial memory deﬁcits, we measured cognition on two
separate measures, Novel Place Recognition (NPR) and the Morris
Water Maze. On both of these measures, ATN TBI animals displayed
long-term cognitive impairment, performing signiﬁcantly worse than
sham animals at N2 months post-injury. First, cognitive function after
TBI was evaluated using the NPR task which measures the amount of
time an animal spends exploring an object located in a novel location
compared to an identical object located in a familiar position. Our re-
sults demonstrate that ATN TBI exhibited spatial memory impairment
via a decrease in novel location exploration (TBI vs. sham: P b 0.001;
Fig. 1B). Additionally, hippocampal-dependent spatial memory deﬁcits
were detected in ATN TBI animals on a second task, the Morris Water
Maze (MWM). MWM latency to platform assessment during both the
acquisition (Fig. 1D) and reversal (Fig. 1F) learning phases revealed
deﬁcits in ATN TBI animals on spatial target location memory as these
animals had signiﬁcantly increased latency to platform times relative
to sham animals. Furthermore, probe trial analysis resulted in similar
ﬁndingswith ATN TBI animals spending less time in the target quadrant
during both the acquisition (TBI vs. sham: P b 0.05; Fig. 1E) and reversal
(TBI vs. sham: P b 0.01; Fig. 1G) learning phases, indicating that ATN TBI
animals did not remember the location of the platform aswell as shams.
TBI ATN rats were also assessed behaviorally on tasks that measure
non-spatial memory, or on tasks that measure emotional/anxiety-
related behavior or classical conditioning. Previous ﬁndings suggest
that non-hippocampal or non-spatial memory impairments are present
after TBI, however deﬁnitive long-term studies in a controlled cortical
impact (CCI) model of TBI have not been conducted in either
immunosufﬁcient or immunodeﬁcient animal models. Accordingly, we
measured non-spatial memory via the Novel Object Recognition
(NOR) task, emotional/anxiety-related behavior via the Elevated Plus
Maze (EPM), and classical conditioning via Conditioned Taste Aversion
(CTA). Our results indicate that CCI TBI at the severity parameters uti-
lized did not create any apparent long-lasting non-spatial, emotional/
anxiety-related, or classical conditioning-related behavioral impair-
ments. No statistically signiﬁcant differences were found between ATN
TBI and sham operated animals in novel object exploration times rela-
tive to a familiar object in the NOR task (TBI vs. sham: P = 0.31;Fig. 1C). Additionally, no differences were found between ATN TBI and
sham animals in the amount of time spent in the open arms of the
EPM (TBI vs. sham: P= 0.10; Fig. 2A) or in the number of entries into
the open arms (TBI vs. sham: P = 0.08; Fig. 2B). Furthermore, no
signiﬁcant differences were demonstrated between ATN TBI and sham
operated animals on the CTA task (Fig. 2C), which was employed as
an additional measure of classical conditioning to determine if TBI ani-
mals would exhibit impairment in associating a noxious event (LiCl-in-
duced gastric malaise associated with saccharin consumption) with an
everyday activity (water/saccharin consumption). Finally, although no
explicit motor function tasks were performed in this study, ATN TBI
and sham operated animals exhibited no differences in either MWM
swim speed or distance traveled during the MWM or EPM tasks (data
not shown), suggesting long-term motor function was not impaired
by TBI.
Together, these results suggest that following a single, moderate-
to-severe unilateral CCI TBI to the hippocampus and overlying
cortex, immunodeﬁcient ATN rats exhibit long-term hippocampal-
dependent spatial memory deﬁcits (NPR, MWM). In contrast, ATN
performance on non-spatial or non-hippocampal-dependent memo-
ry tasks (NOR, EPM, CTA) remains indistinguishable from sham
when tested at time points N2 months post-TBI.
3.2. hNSC transplantation improves long-term cognitive recovery following
TBI
We next sought to determine whether hNSC transplantation could
improve cognitive performance following TBI. To test this hypothesis,
Xeno-Free CD133-enriched hNSCs were transplanted 9 days post-TBI
into 4 sites (anterior medial corpus callosum, posterior medial corpus
callosum, anterior dorsal hippocampus, posterior dorsal hippocampus)
on the contralateral (uninjured) hemisphere of immunodeﬁcient ATN
rats. Following transplantation, animals were assessed behaviorally
using the same hippocampal-dependent spatial memory tasks as
assessed previously (NPR, MWM).
In the NPR task at 8-weeks post-transplant (WPT), ATN TBI animals
receiving vehicle injections performed signiﬁcantly worse compared to
sham animals (TBI + vehicle vs. sham: P b 0.01; Fig. 3B). Transplanta-
tion of high passage (P27) CD133-enriched hNSCs rescued this perfor-
mance deﬁcit as animals receiving high passage hNSCs performed
signiﬁcantly better than ATN TBI animals that received vehicle injection
only (TBI + Shef6 P27 hNSCs vs. TBI + vehicle: P b 0.05; Fig. 3B).
Furthermore, analysis of ATN TBI animals transplanted with high pas-
sage Shef6 hNSCs demonstrated a discrimination index that was statis-
tically indistinguishable from sham-operated ATNs on the NPR task
(TBI + Shef6 P27 hNSCs vs. sham: P = 0.11; Fig. 3B). However, ATNs
transplanted with low passage (P7) CD133-enriched hNSCs did not
exhibit signiﬁcantly improved cognition post-TBI when compared
to vehicle injected ATN TBI animals (TBI + Shef6 P7 hNSCs vs.
TBI + vehicle: P = 0.07; Fig. 3B), suggesting possible differences in
behavioral rescue potential exist within the same cell line at different
passage numbers.
Following TBI, ATN rats also demonstrated spatial memory impair-
ment on the MWM task. However, hNSC transplanted ATNs did not
demonstrate overtly improved cognition as measured by the amount
of time (latency) needed to reach the submerged platform over ﬁve
consecutive days of either acquisition learning (Fig. 3C) or reversal
learning (Fig. 3E) as analyzed by a two-way repeated measures
ANOVA. However, when the animals intra-group learning curves were
assessed over each of the 5 day learning and reversal trials and plotted
as group learning slopes (Rekha et al., 2009), a signiﬁcant shift towards
hNSC transplant-mediated cognitive improvement emerged. Whereas
during the acquisition learning phase all groups exhibited negative (im-
proved) learning slopes (P b 0.001; Fig. 3D), in the reversal learning
phase, ATN TBI animals receiving vehicle injection exhibited a group
learning slope that was statistically equal to zero, indicative of a failure
Fig. 2. Controlled cortical impact TBI does not cause long-term emotional/anxiety-relatedmemory impairment in immunodeﬁcient ATN rats. Between 10 and 16weeks post-TBI, animals
were assessed via the Elevated Plus Maze (EPM) in a dark room and Conditioned Taste Aversion (CTA). No detectable differences were found between TBI and sham animals on the EPM
task as assessed via (A) total time spent in the open arms (one-tailed t-test t20 = 1.35, P = 0.10) or (B) total number of open arm entries (one-tailed t-test t20 = 1.44, P = 0.08).
(C) Similarly, no differences between TBI and sham groups were found in the amount of 0.1% saccharin/water consumed after saccharin/LiCl administration on Day 11. Data are
presented as mean ± s.e.m.
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transplantation appeared to ameliorate this reversal relearning impair-
ment as demonstrated by the negative learning slopes for both sham
and low (P7) passage hNSC (P b 0.001; Fig. 3F) as well as high (P27)
passage hNSC (P b 0.01; Fig. 3F) transplanted animals, further demon-
strating that ATN TBI animals transplanted with hNSCs are better able
to learn novel locations. No differences were observed in Probe trials
for either the acquisition or reversal learning phases, regardless of
group (data not shown).
3.3. hNSC transplantation improves host hippocampal neuron survival
without modiﬁcation of lesion or total spared tissue volumes
Because hNSC transplantation in our study improved hippocampal-
dependent spatialmemory,we sought to determinewhether a histolog-
ical correlate to behavioral recovery existed. First, to quantitatively
assess the long-term impact of both TBI and the subsequent transplan-
tation of hNSCs on lesion size, total spared tissue volume, and ventricle
volume, detailed stereological analysis was performed using the
Cavalieri method (Fig. 4). Stereological analysis conﬁrmed the presence
of a unilateral lesion cavity occupying primarily somatosensory, motor,
and visual cortex regions as well as the underlying corpus callosum and
hippocampus (Fig. 4A–B) on the side of impact. No statistical differences
in cortical or hippocampal volumes on the uninjured hemisphere were
found for any group when compared to sham animals, conﬁrming the
unilateral nature of the injury (data not shown). Following hNSC trans-
plantation, lesion volumes in both the low and high passage hNSC
groups remained unchanged compared to ATN TBI animals given
vehicle injection (Fig. 4C), suggesting that hNSC transplantation in our
study did not decrease lesion size.
Spared tissue and ventricle volume was also assessed. In the
hemisphere ipsilateral to injury, both cortical (TBI + vehicle vs. sham:
P b 0.01; Fig. 4D) and hippocampal (TBI + vehicle vs. sham: P b 0.001;
Fig. 4E) tissue volumes decreased signiﬁcantly post-TBI,with no volume
differences detected between hNSC transplanted and vehicle injected
animals. Along with cortical and hippocampal tissue loss, signiﬁcant
ventricle enlargement post-TBI was also detected (TBI + vehicle vs.
sham: P b 0.01; Fig. 4F), in some cases increasing in volume up to
three-fold, with hNSC transplantation facilitating a downwards, but
not statistically signiﬁcant, trend in ipsilateral ventricular volume.
Taken together, these results demonstrate that TBI at the parameters
utilized leads to the formation of a persistent lesion cavity as well as
decreased cortical and hippocampal tissue volume and ventricularenlargement in the hemisphere ipsilateral to injury. hNSC transplanta-
tion did not signiﬁcantly alter any of these volumetric outcome
measures, yet still managed to effect behavioral recovery, suggesting
the presence of an alternative mechanism(s).
Volumetric quantiﬁcation of affected brain regions after injury
provides an important global view of histological outcome. However,
subtle changes at the cellular level, such as increased host neuron sur-
vival, may be missed with this method. We therefore tested if hNSC
transplantation affects long-term host hippocampal neuronal survival
after TBI via stereological assessment of hippocampal neuronal survival
in both the dentate gyrus (DG) and combined pyramidal cell layers
(CA1, CA2, CA3; referred to as CA). In this study, ATN TBI animals that
received vehicle injection had signiﬁcantly fewer hippocampal neurons
when compared to sham animals in both the DG (TBI + vehicle vs.
sham: P b 0.001; Fig. 5B) and CA (TBI + vehicle vs. sham: P b 0.0001;
Fig. 5C) regions ipsilateral to injury. Transplantation of high passage
(P27) Shef6 hNSCs rescued host neuronal loss in both the DG
(TBI + Shef6 P27 hNSCs vs. TBI + vehicle: P b 0.05; Fig. 5B) and CA
(TBI + Shef6 P27 hNSCs vs. TBI + vehicle: P b 0.05; Fig. 5C) regions.
No differences were found in host neuron survival on the uninjured
(non-impacted side) DG for any TBI group compared to sham animals
(data not shown). ATN TBI animals that received low passage (P7)
Shef6 hNSCs demonstrated a non-signiﬁcant trend towards increased
host neuron survival in these same regions. In parallel, correlation
analysis revealed positive relationships between both host DG neuron
survival (Pearson r = 0.70, P = 0.0003; Fig. 5D) and host CA neuron
survival (Pearson r = 0.64, P = 0.001; Fig. 5E) with performance on
the NPR task, suggesting a strong relationship between hippocampal
neuron survival and cognitive performance.
3.4. Transplanted hNSCs survive long-term and differentiate into cells of all
three neural lineages
Amajor issue that exists in studies transplanting human cell popula-
tions into rodentmodels of TBI is low overall graft survival, likely due to
human-to-rodent xenograft histocompatibility issues and graft
rejection. Immunodeﬁcient ATN rats, which are both T- and B-cell deﬁ-
cient, were therefore used in our study to limit the graft rejection re-
sponse. At 20-weeks post-transplantation, surviving hNSCs (SC121+)
exhibited engraftment throughout the host brain, extending into
ventral hippocampal and ventral/medial cortical regions as well as
occasionally crossing into the injured (non-transplanted) hemisphere
(Fig. 6A, D–F). Of the initial 250,000 hNSCs transplanted 9-days
Fig. 3. Transplantation of hNSCs improves cognitive behavioral outcomes after TBI. Between 8 and 12 weeks post-transplantation (9–13 weeks post-TBI), (A) animals were assessed for
improvements in cognition via both NPR and MWM. (B) On the NPR task, TBI animals given vehicle injections only (n= 11) performed signiﬁcantly worse than sham animals (n = 10,
two-tailed t-test t10= 4.27, P b 0.01). TBI animals that received high passage (P27) hNSCs (n= 11) exhibited a signiﬁcant increase in their novel place exploration ratio during the ﬁrst
2 min of testing as compared to TBI animals that received vehicle injections only (two-tailed t-test t20= 2.58, P b 0.05). TBI+ Shef6 P27 hNSC animals were indistinguishable from sham
animals (two-tailed t-test t10= 1.76, P= 0.11) and signiﬁcantly different from zero (two-tailed t-test t10= 2.78, P b 0.05). TBI animals given low passage (P7) hNSCs (n= 10) did not
exhibit increased exploration compared to vehicle injected TBI animals (two-tailed t-test t19=1.93, P=0.07) and performed signiﬁcantlyworse than shamanimals (n=10, two-tailed t-
test t9 = 2.63, P b 0.05). (C) Analysis of MWM acquisition escape latency revealed that on Days 2–5, TBI animals given vehicle injection or hNSCs had signiﬁcantly increased escape
latencies ﬁnding the hidden platform relative to sham animals. Two-way repeated measures ANOVA was signiﬁcant for trial day (P b 0.0001), group (P b 0.0001), and trial × group
interaction (P b 0.05). No signiﬁcant differences were detected between TBI animals given vehicle injection only and TBI animals given hNSCs (P27 or P7). (D) Analysis of the slope of
acquisition via linear regression revealed signiﬁcantly non-zero slopes for all groups during MWM acquisition (P b 0.001). (E) MWM reversal escape latency analysis revealed that on
Days 7–11, TBI animals given vehicle injection or hNSCs had signiﬁcantly increased escape latencies ﬁnding the hidden platform relative to sham animals. Two-way repeated measures
ANOVA was signiﬁcant for trial day (P b 0.0001) and group (P b 0.0001), but not for trial × group interaction (P= 0.11). No signiﬁcant differences were detected between TBI animals
given vehicle injection only and TBI animals given hNSCs (P27 or P7). (F) Analysis of the slope of acquisition via linear regression revealed signiﬁcantly non-zero slopes for sham and
TBI animals given Shef6 P7 (P b 0.001) or Shef6 P27 hNSCs (P b 0.01) during MWM reversal, however TBI animals given vehicle injection only were statistically indistinguishable from
zero (P= 0.36). All data is from analysis conducted 20 weeks post-hNSC transplantation/vehicle injection. #represents comparisons made to sham animals. *represents comparisons
made between groups (A, B, D) or compared to zero slope (C, E). #/*P b 0.05, ##/**P b 0.01, ###/***P b 0.001. Data are presented as mean ± s.e.m.
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enriched hNSCs and 62,201 ± 17,397 (or 24.9% ± 7.0) low passage
P7 CD133-enriched hNSCs survived long-term (Fig. 6B). However,
correlations of transplanted hNSC survival with cognitive improve-
ments were not statistically signiﬁcant (Fig. 6C). Overall, while thetotal transplanted hNSC survival estimates in this study may seem
low in comparison to that typically observedwhen using immunode-
ﬁcient animals for human cell transplantation studies in a variety of
neurological disease and injuries (Anderson et al., 2011), the extent
of transplanted cell survival in this study demonstrates a dramatic
Fig. 4. Controlled cortical impact TBI causes long-term tissue loss and ventricular swelling that is not resolved via hNSC transplantation. (A) 3-D volumetric reconstruction of lesion (red),
hippocampus (orange), and ventricular space (blue) at 20 weeks post-transplantation. (B) Representative histological section depicting extent of long-term damage resulting from CCI-
TBI. Volumetric analysis of (C) lesion volume demonstrates signiﬁcant lesion formation in all TBI groupswhen compared to sham animals (two-tailed t-test, P b 0.0001) with no change in
lesion size as a result of hNSC transplantation. As a result of TBI, there is (D) a signiﬁcant reduction in ipsilateral cortical tissue volume in vehicle injected animals when compared to sham
(two-tailed t-test t5=5.86, P b 0.01), (E) a signiﬁcant reduction in ipsilateral hippocampal tissue volume in vehicle injected animalswhen compared to sham (two-tailed t-test t5=7.74,
P b 0.001) aswell as (F) a signiﬁcant increase in ipsilateral lateral ventricle volume in vehicle animalswhen compared to sham (two-tailed t-test t5=6.18, P b 0.01). hNSC transplantation
did not alter either cortical or hippocampal tissue loss, or lateral ventricle swelling. All data is from analysis conducted 20weeks post-hNSC transplantation/vehicle injection. #represents
comparisons made to sham animals. *represents comparisons made between groups. #/*P b 0.05, ##/**P b 0.01, ###/***P b 0.001. Data are presented as mean ± s.e.m.
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cell survival speciﬁcally in rodent models of TBI (Gold et al., 2013).
Previously, we have found that when transplanted into a naïve
immunodeﬁcient host, the cell population used in this study differenti-
ates predominantly into neurons (Haus et al., 2014). Similarly, cell fate
analysis in this study demonstrated that the predominant terminal
fate of transplanted hNSCs was neuronal, with 18.6 ± 4.1% of high
passage (P27) Shef6 hNSCs and 37.6 ± 2.0% of low passage (P7) Shef6
hNSCs differentiating into NeuN+ neurons (Shef6 P27 vs. Shef6 P7:
P b 0.01; Fig. 7A–B). However, a smaller percentage of both astrocytic
(GFAP) (Shef6 P27, 13.2 ± 3.4%; Shef6 P7, 15.8 ± 3.2%; Fig. 7C–D) and
oligodendroglial (Olig2) (Shef6 P27, 11.3 ± 1.7%; Shef6 P7, 13.1 ±
2.5%; Fig. 7E–F) differentiation was found to be present, suggesting
that the TBImicroenvironmentmay inﬂuence the in vivo differentiationpotential of transplanted embryonic-derived hNSCs. Additionally, a sig-
niﬁcant portion of transplanted hNSCs remained in an undifferentiated
(Nestin+) state, even at 20-weeks post-transplantation (Shef6 P27,
9.7 ± 6.3%; Shef6 P7, 23.9 ± 5.3%; Fig. 7G–H).
4. Discussion
4.1. Validating long-term cognitive deﬁcits in an immunodeﬁcient rodent
model of TBI
TBI research in animalmodels to date has primarily focused on short
term (hours to days) histological and behavioral outcomes (Marklund
andHillered, 2011; Xiong et al., 2013).While such studiesmay be infor-
mative for assessing the acute response to various forms of intervention,
Fig. 5. hNSC transplantation rescues host hippocampal neuron loss after TBI. (A) Representative image reconstructions of host neuron quantiﬁcation in hippocampal dentate gyrus (DG)
(purple circles) and cornu ammonis (CA) (blue circles) regions. Lesion is outlined in red. (B\\C) Quantiﬁcation of host hippocampal neuron survival in the injured DG and CA regions.
When compared to sham animals, signiﬁcant neuronal loss is present in vehicle injected TBI animals in both the (B) injured DG (two-tailed t-test t5 = 9.76, P b 0.001) and (C) injured
CA (two-tailed t-test t5 = 12.29, P b 0.0001). When compared to vehicle injected TBI animals, transplantation of high passage (P27) Shef6 hNSCs prevents neuronal loss in both the
(B) injured DG (two-tailed t-test t9 = 2.33, P b 0.05) and (C) injured CA (two-tailed t-test t9 = 2.49, P b 0.05). Transplantation of low passage (P7) Shef6 hNSCs had no effect on
neuronal survival after TBI in either region. (D–E) Linear regression analysis revealed signiﬁcant positive correlations between (D) host DG cell survival and NPR score (Pearson r=
0.70, P = 0.0003, one-tailed t-test) and (E) host CA cell survival and NPR score (Pearson r = 0.64, P = 0.001, one-tailed t-test). All data is from analysis conducted 20 weeks post-
hNSC transplantation/vehicle injection. #represents comparisons made to sham animals. *represents comparisons made between groups. #/*P b 0.05, ##/**P b 0.01, ###/***P b 0.001.
Data are presented as mean ± s.e.m.
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lasting therapeutic efﬁcacy and to ensure that any behavioral gains are
due to treatment and not spontaneous recovery (Nudo, 1999; Gold
et al., 2013). Furthermore, the need for long-term studies is particularly
important when the therapy being evaluated involves the transplanta-
tion of human neural stem cells that may require several weeks-to-
months to integrate and mature in vivo.
Therefore, we ﬁrst characterized a battery of potential long-term
cognitive behavioral impairments following TBI in immunodeﬁcient
ATN rats. This is the ﬁrst report of these measures in ATN rats using a
controlled cortical impact (CCI) model of TBI. In this study, immunode-
ﬁcient ATN rats demonstrated hippocampal-dependent spatial memory
deﬁcits at 2–3 months post-injury (NPR, MWM), thus conﬁrming that
cognitive deﬁcits that are typically present after TBI in common
immunosufﬁcient animal strains are also present after TBI in immuno-
deﬁcient ATN rats and persist for several months after injury. However,
the same brain-injured animals did not demonstrate long-term
cognitive impairment on either a non-spatial memory task (NOR) or
on measures that test anxiety or emotional memory (EPM, CTA).
Interestingly, previous studies have reported cognitive impairment
after TBI on non-spatial memory or anxiety measures (Gold et al.,
2013). However, themajority of these studies did not evaluate cognitivebehavior at long-term (≥2 months) time points after injury. Of the few
studies that did evaluate behavior at timepoints N2months post-injury,
one group reported EPM and Forced Swim impairments that were
shown to persist until 2 months post-injury (Shultz et al., 2012; Shultz
et al., 2013), and in a second set of studies, Forced Swim and Passive
Avoidance impairments were present up to 2–3 months post-TBI
(Milman et al., 2005;Milman et al., 2008). In each of these studies, how-
ever, the injuries were generated by diffuse methods (Lateral Fluid
Percussion Injury and Weight-Drop, respectively). Conversely, our
injury paradigm (CCI) generates a more focal injury in which brain
regions critical for non-spatial or anxiety/emotional-related memory
may not have been damaged to the same extent found in studies
utilizing other injury methods, thereby generating shorter-lasting
impairment. However, the alternative possibility that suchmemory def-
icits never existed from the outset in our studymust also be considered
as we only performed cognitive assessments at later time points.
4.2. Evaluating the effects of hNSC transplantation on cognitive recovery
following TBI
To evaluate the potential for hNSC transplant-mediated cognitive
improvement post-TBI, hippocampal-dependent spatial memory was
Fig. 6. Transplanted hNSCs engraft and survive long-term in an immunodeﬁcient rodent model of TBI. (A) 3-D reconstruction of the location of surviving hNSCs at 20 weeks post-
transplantation that engrafted in either cortex (green circles) or hippocampus (red circles). Lesion is outlined in red. (B) Stereological quantiﬁcation of transplanted high passage P27
Shef6 (n = 12, 8.7% ± 4.2) and low passage P7 Shef6 (n = 10, 24.9% ± 7.0) hNSC survival. No statistical difference in transplanted hNSC survival was detected between cell
populations (two-tailed t-test t20 = 2.07, P = 0.052). (C) Linear regression analysis revealed no signiﬁcant correlations between transplanted hNSC survival and NPR score (Shef6
P27, Pearson r= 0.31, P= 0.18; Shef6 P7, Pearson r=−0.22, P= 0.28, one-tailed t-test). (D–E) Immunohistochemistry of transplanted hNSCs (SC121+) demonstrates survival and
engraftment in both the (D) hippocampus and (E) corpus callosum. (F) Percent quantiﬁcation of transplanted hNSC survival in different regions in the injured and uninjured
hemispheres. Red boxes delineate regions shown at higher magniﬁcation. Scale bars for low magniﬁcation images = 150 μm and for high magniﬁcation images = 15 μm. All data is
from analysis conducted 20 weeks post-hNSC transplantation or vehicle injection. Data are presented as mean ± s.e.m.
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of both murine (Riess et al., 2002; Schouten et al., 2004; Bakshi et al.,
2006) and human neural cell types (discussed below) in ameliorating
cognitive dysfunction after TBI, including the transplantation of fetal
human neural stem/progenitor cells (Hagan et al., 2003; Al Nimer
et al., 2004; Wennersten et al., 2004; Gao et al., 2006; Wennersten
et al., 2006; Skardelly et al., 2011; Poltavtseva et al., 2012; Wang et al.,
2012) and human NT2N neurons (Muir et al., 1999; Philips et al.,
2001; Watson et al., 2003; Longhi et al., 2004; Zhang et al., 2005).Critically however, only one of these studies evaluated cognitive
function long-term (2 or more months) after injury and human neural
cell transplantation and reported improvement on a cognitive measure
(Skardelly et al., 2011), further demonstrating the need for more long-
term cognitive behavioral studies to be conducted in the future.
Additionally, the ﬁndings from many TBI and stem cell transplantation
studies are based on methods that may be too heterogeneous to facili-
tate direct comparisons between studies and in some cases, publication
bias may be present as larger studies with higher Quality Index (QI)
Fig. 7. Transplanted hNSCs differentiate into all three neural lineage cell types. At 20weeks post-transplantation, hNSCs differentiate into either (A–B)matureNeuN+neurons (Shef6 P27,
n = 5, 18.6% ± 4.1; Shef6 P7, n = 6, 37.6% ± 2.0; Shef6 P27 vs. Shef6 P7, two-tailed t-test t9 = 4.36, P b 0.01), (C–D) GFAP+ astrocytes (Shef6 P27, n = 4, 13.2% ± 3.4; Shef6 P7, n = 6,
15.8% ± 3.2), and (E–F) Olig2+ oligodendrocytes (Shef6 P27, n = 5, 11.3% ± 1.7; Shef6 P7, n = 6, 13.1% ± 2.5), or remain (G–H) undifferentiated and express Nestin (Shef6 P27, n = 5,
9.7%±6.3; Shef6 P7, n=6, 23.9%±5.3). For all images, red channel represents SC121+(human) cells. Green channel represents speciﬁed cell fate.White arrows indicate examples of co-
localized cells. Scale bars = 15 μm (40× images) or 6 μm (100× images). All data is from analysis conducted 20 weeks post-hNSC transplantation/vehicle injection. **P b 0.01. Data are
presented as mean ± s.e.m.
12 D.L. Haus et al. / Experimental Neurology 281 (2016) 1–16scores often have smaller effect sizes than small studies with low QI
scores (Chang et al., 2015).
While recent studies have reported the successful engraftment and
survival of human pluripotent-derived stem cells in rodent models of
TBI, including the demonstration of human induced pluripotent stem
cell (hiPSC) derived NSC engraftment and cell tracking (Tang et al.,
2013) as well as the ﬁrst demonstration of successful hESC-derived
oligodendrocyte progenitor cell (OPC) engraftment in an ATN TBI
model (Xu et al., 2015), to our knowledge, zero studies to date have
been conducted assessing the effects of hESC-NSC transplantation in
modulating cognitive function after TBI. Our study therefore is the ﬁrst
demonstration of hESC-NSC transplant-mediated recovery of cognitive
function post-TBI. ATN TBI animals transplanted with hNSCs demon-
strated signiﬁcant improvement on both the NPR and MWM tasks.
However, the MWM improvement was observed only in the reversal
phase and also only when learning slopes were analyzed, not latency
to platform. The reversal phase of MWM is considered to be more
challenging than acquisition as it requires animals to both extinguish a
previously learned location and then learn a new one (Vorhees and
Williams, 2006). Multiple examples exist where experimental animals
show little to no differences during acquisition but exhibit strong
deﬁcits during reversal (Vorhees and Williams, 2014), particularly in
the case of hippocampal damage. In our MWM reversal assessment,
sham animals from the outset quickly learned the new platform
location. However, all ATN TBI animals took considerably longer,
suggesting a slower learning process. By looking then at learning slopes,
we can observe that ATN TBI animals given vehicle only never
demonstrate any improvement (zero slope) during reversal testing.Conversely, ATN TBI animals transplanted with hNSCs do demonstrate
improvement (negative slope), and their rate of learning (slope) is
nearly identical to that of sham animals. Together with the improve-
ment observed on the NPR task, these data suggest an overall net posi-
tive effect on cognitive improvement post-TBI in animals transplanted
with hNSCs.
4.3. Evaluating the effects of hNSC transplantation on histological outcome
measures following TBI
In this study, unbiased stereological methods were used to quantify
the effect hNSC transplantation has on modulating histological mea-
sures such as lesion volume, spared cortical and hippocampal tissue
volume, ventricle volume, and host hippocampal neuron survival.
Very few studies have assessed the effects that human fetal neural pro-
genitor (Skardelly et al., 2011) or NT2N neuron (Philips et al., 2001;
Vaysse et al., 2015) transplantation has on reducing lesion volume
and/or increasing host neuronal survival. Skardelly et al., found that
human fetal progenitor cell transplantation decreased lesion size as
measured by T2-weightedMRI at 2.5months post-injury/cell transplan-
tation and also increased neuronal survival at 3 months post-injury/cell
transplantation in the cortex adjacent to the site of injury. However, as
only motor related behavioral impairments were measured, not cogni-
tion, hippocampal neuron survival was not assessed. Additionally,
Philips et al. reported an increase in hippocampal CA3 pyramidal cell
survival after NT2N neuron transplantation. However, this effect was
measured only 1 day after cell transplantation; whether this improve-
ment persisted long-term is unknown. Finally, Vaysse et al. recently
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injection of a biomaterial scaffold seeded with hNT2 neurons, but this
assessment was by qualitative measures only. Furthermore, while all
of these studies demonstrated improvement in some behavioral
measures, no analysis of the potential associations between behavioral
improvement and decreased lesion volumes or increased neuronal
survival after cell transplantation were performed.
Todetermine if persistent histological changes occur after transplan-
tation of hNSCs into an immunodeﬁcient rat model of TBI, we ﬁrst
assessed lesion volume (as well as spared cortical and hippocampal
tissue volume and ventricle volume) stereologically. Our results indi-
cate that at 5 months post-transplantation, an approximately 60 mm3
lesion existed in all ATN TBI animals, regardless of whether given
vehicle injection or transplanted with hNSCs. One possibility for why
no difference was found in hNSC transplanted animals could have
been that the injury itself in our study was too severe and the damaged
caused by the initial insult was beyond repair. However, pilot studies in
our lab revealed that this level of injury was necessary in order for ATNs
to develop persistent long-term cognitive deﬁcits. Two other possibili-
ties could be that 1) the delayed nature of our cell transplantation
paradigm (hNSCs transplanted 9 days post-injury) did not allow for
an early enough intervention to prevent or modulate the initial post-
injury wave of damage, and/or that 2) the transplantation of hNSCs
into the hemisphere contralateral to injury (as was done in our study)
did not allow for the transplanted cells to directly participate in events
occurring within or adjacent to the forming lesion.
However, we hypothesized that maximizing transplanted cell
survival was of greater importance to behavioral recovery than
minimizing lesion size or tissue loss, and previous studies have
implicated both transplantation timing as well as location in regards
to transplanted cell survival. Analysis of murine NSCs transplanted 2,
7, and 14 days post-TBI demonstrated that cells transplanted at 7 days
post-TBI exhibited the highest degree of cell survival (Shear et al.,
2011). This ﬁnding is in line with previous speculation that 9 days
post-injury in the CNS is the optimal time for cell transplantation
(Okano et al., 2003; Nakamura and Okano, 2013). However, we have
previously compared graft survival of hNSCs transplanted into various
rodent models of contusion spinal cord injury at 9, 30 and 60 days
post-injury and have found that the timing of transplantation doesn't
appear to limit cell survival (Cummings et al., 2005; Hooshmand et al.,
2009; Salazar et al., 2010; Piltti et al., 2013b). However, both the
differentiation potential and migration patterns of transplanted hNSCs
were affected, suggesting that transplantation timing should be given
careful consideration when designing future studies. Transplant
location also appears to play a role in cell survival, although deﬁnitive
conclusions remain controversial. Human fetal neural stem cells, when
transplanted into either an injured spinal cord environment compared
to uninjured spinal cord (Sontag et al., 2014), or into the injury
epicenter compared to locations rostral/caudal to injury (Piltti et al.,
2013a), exhibited decreased survival, suggesting that the injury
microenvironment may be prohibitive to transplanted cell survival.
Conversely, murine NSCs transplanted into the injured hemisphere
after mild TBI exhibited increased survival compared to cells
transplanted into the contralateral (uninjured) hemisphere (Shear
et al., 2011). However, considering the source of the NSCs used in our
study (human) and the injury severity (moderate/severe), we chose
to transplant the hNSCs 9 days post-TBI into the hemisphere
contralateral to TBI in an attempt to maximize the potential for
transplanted cell survival and behavioral recovery. Ultimately, even
though no differences were found in either lesion size or cortical/hippo-
campal tissue volume due to hNSC transplantation, cognition was still
rescued in hNSC transplanted ATN TBI animals, highlighting that restor-
ative TBI therapies need not necessarily focus primarily on reducing
lesion size or tissue loss.
Given then that cognitive improvement was found in the absence of
reduced lesion volume or increased cortical/hippocampal tissue volumeafter hNSC transplantation in ATN TBI animals, host hippocampal
neuron survival was assessed to determine if differences existed
between vehicle and hNSC transplanted animals at the cellular level
that could account for the observed behavioral improvement. Previous
studies have found that the rodent hippocampus is particularly vulner-
able to TBI (Baldwin et al., 1997; McCullers et al., 2002; Anderson et al.,
2005; Hall et al., 2005), and there is longstanding evidence for cognitive
deﬁcits in rodents with hippocampal neuronal cell loss (Volpe et al.,
1992; Conrad and Roy, 1993). In these studies, lesions to speciﬁc
hippocampal subregions or surgical procedures that result in region
speciﬁc hippocampal neuron loss, including neuronal loss in the DG
and CA1 regions, caused subsequentmemory impairment. Additionally,
similar ﬁndings have been demonstrated in genetic models of hippo-
campal neuronal loss (Yamasaki et al., 2007; Myczek et al., 2014),
accelerated aging models (Li et al., 2013), models of epilepsy (Silva
et al., 2013), early life stress (Brunson et al., 2001), ischemic stroke
(Kirino, 1982; Hartman et al., 2005), and TBI (Hicks et al., 1993; Scheff
et al., 1997, 2005; Lu et al., 2007). Considering that a loss of hippocampal
neurons results in cognitive decline, the reverse may be true in that
preventing this loss could lead to cognitive improvement. In our
study, we found a signiﬁcant decrease in hippocampal neurons in both
the dentate gyrus (DG, 46% decrease) and cornu ammonis (CA, 62%
decrease) zones of ATN TBI animals given vehicle injection that was
largely prevented by the transplantation of high passage Shef6 hNSCs.
Furthermore, signiﬁcant positive relationships were found between
hippocampal DG and CA number with behavioral improvement on the
NPR task, suggesting that a possible link exists between increased hip-
pocampal neuron number and improvement in cognitive function
after TBI.
However, even though hNSC transplanted animals exhibited
increased hippocampal neuronal sparing and cognitive behavioral
improvement, caution should still be exercised to not over-interpret
this relationship as causal in the absence of data demonstrating a direct
link. Additionally, potential mechanisms for behavioral improvement
beyond increased hippocampal neuron survival likely also exist as the
extent of behavioral recovery in this study was not complete. Further-
more, the question of whether cell integration, trophic support, or
possibly immune modulation is ultimately responsible for histological
and behavioral improvement (Snyder et al., 2004) remains to be deter-
mined. As a ﬁrst step towards elucidating possible histological
correlates to behavioral recovery in this study, we assessed hippocam-
pal neuron survival due to its established relationship with spatial
memory. However, our model of TBI also produces signiﬁcant cortical
damage, which has been suggested to play an important (Brutkowski,
1965; Kolb, 1984) but controversial (Nudo, 1999) role in cognition
following injury or lesion, but we have yet to evaluate in great detail
cortical function after TBI and hNSC transplantation. Future studies
will therefore need to assess in greater detail the extent to which stem
cell transplantation, and, perhaps importantly, long-term transplanted
cell survival contributes to improved host histopathological outcome
to determine more precisely the mechanism(s) of action leading to
behavioral recovery.
4.4. Assessing transplanted hNSC survival, fate, and migration
To determine the extent to which the transplanted hNSCs survived
long-term (5 months) after TBI, we quantiﬁed human cell survival
stereologically. Previously, the same population of CD133+/CD34−
Shef6 hNSCs utilized in this present study were transplanted into im-
munodeﬁcient NOD-scid mice and did not exhibit any evidence of
non-neural differentiation at 12-weeks post-transplant (Haus et al.,
2014). However, due to the lengthened duration of this present study
(20-weeks post-transplant), high passage (P27) Shef6 hNSCs were
transplanted in addition to low passage (P7) Shef6 hNSCs in the event
that low passage hNSCs were not fully neuralized so as to avoid the
potential for teratoma formation (Seminatore et al., 2010). Additionally,
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from transplanted embryonic stem cells may be increased in the
presence of an innate inﬂammatory response (Chen et al., 2014b) that
would likely be found following TBI and stem cell transplantation,
which further argues for the use of long-term cultured, stable hNSC
lines. Historically, transplanted human cell survival in immunosufﬁcient
animal models of CNS injury and disease (for example, studies using
C57Bl6 mice or Sprague Dawley rats) has been shown to be quite
poor, even when immunosuppressive drugs were administered
(Anderson et al., 2011). In the TBI ﬁeld to date, only two studies have
quantiﬁed the number of surviving transplanted human neural cells
(Hagan et al., 2003; Wennersten et al., 2006). Both studies reported
the terminal amount of surviving human cells to be b1% of the original
transplant dose. In our study, which utilized immunodeﬁcient ATN rats
as the host, we observed greatly improved transplanted human cell
survival (9–25%), although not as robust as observed with fetal hNSC
transplants into spinal cord injured ATN rats (Piltti et al., 2013a). Inter-
estingly, we found that high passage hNSCs, which appear to have a
greater beneﬁcial effect in facilitating behavioral recovery compared
to low passage hNSCs and also resulted in greater host hippocampal
neuron survival, survived to a lesser extent than low passage hNSCs
(9% vs. 25%, respectively). These ﬁndings suggest that even though
b10% of the original dose of high passage hNSCs survived long-term,
these cells were still able to exert a promising beneﬁcial effect on
cognitive recovery after TBI. However, the question of whether a higher
number of cells survived initially and were slowly lost over time, or if
only a small amount survived initially and remained throughout the
course of the study, still has yet to be answered.
Interestingly, a previous study using this same hNSC cell population
demonstrated a neuronal fate preference both in vitro and after
transplantation into an uninjured immunodeﬁcient host (Haus et al.,
2014). Additionally, the transplanted hNSCs exhibited limitedmigration
away from the transplant site. However, in the present study, in re-
sponse to injury, transplanted hNSCs exhibited a broader differentiation
proﬁle and also migrated to a greater extent than in the naïve host. We
examined transplanted hNSC fate and found that while the highest
percentage of hNSCs still differentiated into NeuN+ neurons (19–
38%), astrocyte (13–16%) and oligodendrocyte (11–13%) differentiation
readily occurred. Additionally, a signiﬁcant percentage of cells appeared
to remain undifferentiated and continued to express Nestin (10–24%)
even after 20 weeks of in vivo maturation. These ﬁndings suggest that
not just one cell type (for example: neurons) may be important for
facilitating cognitive recovery after TBI.
3D reconstructions and regional quantiﬁcation of transplanted cell
survival demonstrate that many cells migrate away from the transplant
site, with some even entering the contralateral (injured) hemisphere
and others migrating to the more ventral aspects of the hippocampus
and cortex. A recent study published by Xu et al., reporting for the ﬁrst
time the use of ATN rats in a TBI/cell transplantation model, demon-
strated contralateral migration of transplanted hESC-derived OPCs
after TBI (Xu et al., 2015), providing further evidence of the migratory
potential of human pluripotent-derived stem cells when transplanted
after injury. In the clinical setting, transplanted cell migration will likely
be a very important consideration. By having a cell population that is
migratory, patients will require fewer injections. In our study, we have
transplanted cells into 4 different sites (3 total needle tracts) in the
hemisphere contralateral to the injury. The location of the transplanta-
tion sites was chosen tomaximize transplanted cell health (by injecting
them distal to the injury site) and also to maximize the potential
for transplanted cell migration (by injecting them into the corpus
callosum). Our ﬁnding that TBI animals receiving hNSC injections in
this manner demonstrated improved cognitive function compared to
TBI animals receiving vehicle injection supports the effectiveness of
this approach. However, even though many of the transplanted hNSCs
in our study did exhibit migration away from the injection site, a
signiﬁcant portion remained in adjacent areas, demonstrating theneed for further improvements to be made in enhancing the migration
of transplanted pluripotent-derived hNSCs.
5. Conclusions
In summary, we have shown that hippocampal-dependent spatial
memory impairments exist in an immunodeﬁcient ATN model of
cortical impact TBI, and that these impairments persist long-term
(N2–3 months). Furthermore, we have demonstrated that in this
model of TBI, transplanted hNSCs survive to a greater extent compared
to previous TBI xenotransplantation studies utilizing immunosufﬁcient
animals given immunosuppressive drugs, and that transplantation of
hNSCs restores cognitive function after TBI. Importantly, recovery of
cognitive function was achieved without large-scale modiﬁcations of
lesion or spared tissue volume, suggesting that therapies aimed at im-
proving cognition after brain injury do not necessarily need to prevent
tissue loss or reduce lesion volume. Instead, the focus could be centered
on modulating the microenvironment within the surviving host tissue
to increase, for example, hippocampal neuron survival, which in this
study was found to be associated with improved cognitive behavioral
recovery. Additionally, some evaluated measures of behavioral recov-
ery, but not all, were improved in this study with the survival of only
9–25% of transplanted hNSCs, suggesting the possibility that further
cognitive improvement might be possible if a greater percentage of
transplanted human cells survive. Future studies will need to be con-
ducted to evaluate whether increasing the transplantation dose, and
thereby potentially increasing the amount of surviving transplanted
cells, will lead to further cognitive gains. Additionally, transplantation
of different cell types, including fetal- and iPS-derived hNSCs, should
also be evaluated in order to determine if an optimal cell population
exists to aide in the recovery of cognitive function after TBI.
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